N.T. reports consultancy agreements with Marizyme, Mesentech, PulseData and Renibus; ownership interests in ClinPredict, Klinrisk, Marizyme, Mesentech, PulseData, Quanta and Renibus; receiving research funding from AstraZeneca, Bayer, BI-Lilly, Janssen and Otsuka; receiving honoraria from AstraZeneca, Bayer, BI-Lilly, Janssen, Otsuka Pharmaceuticals and Pfizer; having patents or royalties with Klinrisk and Marizyme; having an advisory or leadership role with ClinPredict and Klinrisk; other interests or relationships with the National Kidney Foundation; and being the founder of ClinPredict and Klinrisk. C.S. reports no competing interests.